hutchmed china said friday that its fruquintinib cancer treatment has been granted a priority review of the new drug application by the us food and drug administration the londonlisted biopharmaceutical company said that if approved fruquintinib will be the first and only highly selective inhibitor of all three vascular endothelial growth factor receptors approved in the us for previously treated metastatic colorectal cancer hutchmed said the fda plans to complete the review process by nov 30 fruquintinib is approved in china as a treatment for refractory metastatic colorectal cancer the company said todays acceptance marks a significant advancement towards the goal of providing patients with previously treated metastatic colorectal cancer a muchneeded therapeutic option given the limited treatment options currently available to patients the company said